Anti-HM1-24 monoclonal antibody

Drug Profile

Anti-HM1-24 monoclonal antibody

Alternative Names: AHM

Latest Information Update: 12 Nov 2004

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chugai Pharmaceutical; University of Tokushima
  • Developer Chugai Pharma Europe
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma

Highest Development Phases

  • Discontinued Multiple myeloma

Most Recent Events

  • 12 Nov 2004 Discontinued - Phase-I for Multiple myeloma in United Kingdom (Injection)
  • 04 Nov 2002 Chugai Pharmaceutical has been acquired by Roche
  • 10 May 2001 Anti-HM1-24 has received orphan drug status for multiple myeloma in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top